Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 13/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10092296 | 0.88 | TACR1 (0.45) | TACR1RAB9A | |
| SCHEMBL16409056 | 0.88 | ALDH1A1 (0.47) | — | |
| Trifluoroacetic Acid SCHEMBL13731716 | 0.76 | ALDH1A1 (0.48) | — | |
| Trifluoroacetic Acid SCHEMBL14763245 | 0.76 | MMP1 (0.46) | — | |
| SCHEMBL16197553 | 0.75 | MME (0.47) | — | |
| SCHEMBL15292153 | 0.75 | MME (0.47) | — | |
| SCHEMBL27256763 | 0.75 | MME (0.47) | — | |
| SCHEMBL16197554 | 0.75 | MME (0.47) | — | |
| SCHEMBL18812052 | 0.75 | MME (0.47) | — | |
| SCHEMBL20454197 | 0.75 | MME (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150023989-A1 | NEW ANTIBODY DRUG CONJUGATES (ADCS) AND THE USE THEREOF | SEATTLE GENETICS, INC. | 2015-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150023989-A1 | NEW ANTIBODY DRUG CONJUGATES (ADCS) AND THE USE THEREOF | FGFR2, FGFR1, FGFR3 | TACR1 487/4885RAB9A 2095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.